Advertisement
Screener

Vir Biotechnology, Inc. (VIR) EBITDA

Vir Biotechnology, Inc. (VIR) EBITDA

  • 2026-06-30: Basis Reported; EBITDA $76.27M*; Operating income $73.47M; Depreciation and amortization $2.80M*.
  • 2026-03-31: Basis Reported; EBITDA -$129.48M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$45.02M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$170.44M*; Operating income -$173.44M; Depreciation and amortization $3.00M*.

Complete source-backed ebitda history.

Available history
2017-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported$76.27M*$73.47M$2.80M*(m)(m)$32.00K*$123.33M*(m)$135.28M$30.20M$179.00K
2026-03-31Reported-$129.48M(m)(m)(m)446479.31%$390.00K-$132.39M(m)$108.92M$23.34M$170.00K
2025-12-31Reported-$45.02M(m)(m)(m)-70.27%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$170.44M*-$173.44M$3.00M*$240.00K-71018.75%*$317.00K*-$167.57M*(m)$151.46M$22.23M$168.00K
2025-06-30Reported-$115.50M*-$118.42M$2.92M*$1.21M-9514.00%*$2.54M*-$120.22M*(m)$97.51M$22.28M$170.00K
2025-03-31Reported-$136.68M(m)(m)(m)-4507.92%$1.63M-$78.12M(m)$118.64M$23.94M$16.00K
2024-12-31Reported-$114.26M(m)(m)(m)-923.42%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$228.41M*-$231.30M$2.90M*$2.38M-9596.97%*$2.77M*-$171.48M*(m)$195.18M$25.74M$177.00K
2024-06-30Reported-$154.37M*-$158.63M$4.26M*$3.08M-5020.16%*$666.00K*-$77.85M*(m)$105.11M$30.27M-$1.51M
2024-03-31Reported-$75.56M(m)(m)(m)-134.04%$1.87M-$109.39M(m)$100.13M$36.32M$276.00K
2023-12-31Reported-$134.54M(m)(m)(m)-801.44%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$182.23M(m)(m)(m)-6905.34%$3.71M*-$155.83M*(m)$145.03M$40.93M-$3.21M
2023-06-30Reported-$210.59M(m)(m)(m)-5546.12%$9.46M*-$389.25M*(m)$168.08M$45.51M-$2.85M
2023-03-31Reported-$137.73M(m)(m)(m)-218.77%$6.87M-$125.78M(m)$157.64M$46.78M-$2.23M
2022-12-31Reported-$148.15M(m)(m)(m)-299.84%(m)(m)(m)(m)(m)(m)
2022-09-30Reported$196.56M(m)(m)(m)52.48%$18.99M*$117.90M*(m)$114.17M$43.17M$42.42M
2022-06-30Reported-$223.72M(m)(m)(m)550.65%$20.60M*$960.14M*(m)$115.08M$41.59M-$157.23M
2022-03-31Reported$1.02B(m)(m)(m)82.38%$15.84M$550.09M(m)$90.23M$38.26M$403.29M
2021-12-31Reported$573.14M(m)(m)(m)70.52%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$51.99M(m)(m)(m)-50.17%$6.01M*-$105.81M*(m)$98.67M$50.50M$334.00K
2021-06-30Reported$62.32M(m)(m)(m)35.19%$2.08M*$140.06M*(m)$86.13M$28.78M$53.00K
2021-03-31Reported-$157.36M(m)(m)(m)-7963.77%$667.00K-$89.53M(m)$134.87M$25.74M$196.00K
2020-12-31Reported-$107.19M(m)(m)(m)-6181.60%(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$86.52M(m)(m)(m)-4487.29%$1.47M*-$49.84M*(m)$70.68M$18.86M$22.00K
2020-06-30Reported-$27.95M(m)(m)(m)-41.73%$1.34M*-$10.64M*(m)$79.65M$16.39M$46.00K
2020-03-31Reported-$70.91M(m)(m)(m)-1240.12%$1.30M-$48.41M(m)$64.98M(m)$16.00K
2019-12-31Reported-$62.9M(m)(m)(m)-6418.37%(m)(m)(m)(m)(m)(m)
2019-09-30Reported-$46.78M(m)(m)(m)-3334.28%$1.26M*-$36.95M*(m)$39.86M(m)-$13.00K
2019-06-30Reported-$34.97M(m)(m)(m)-1708.30%$2.65M*-$24.30M*(m)$29.80M(m)$19.00K
2019-03-31Reported-$30.06M(m)(m)(m)-821.20%$3.48M-$29.49M(m)$25.87M(m)(m)
2018-12-31Reported-$26.2M(m)(m)(m)-838.23%(m)(m)(m)(m)(m)(m)
2018-09-30Reported-$33.95M(m)(m)(m)-1176.64%(m)(m)(m)$29.84M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$467.65M(m)(m)(m)-682.14%$4.83M-$391.78M(m)$455.97M$92.07M$217.00K
2024-12-31Reported-$572.61M(m)(m)(m)-771.65%$7.30M-$446.35M(m)$506.50M$119.03M-$1.15M
2023-12-31Reported-$664.85M(m)(m)(m)-771.47%$21.57M-$778.78M(m)$579.72M$174.44M-$13.08M
2022-12-31Reported$839.85M(m)(m)(m)51.98%$68.01M$1.66B(m)$474.65M$161.76M$238.44M
2021-12-31Reported$426.03M(m)(m)(m)38.89%$21.82M-$47.59M(m)$448.01M$160.79M$21.22M
2020-12-31Reported-$292.58M(m)(m)(m)-383.12%$6.55M-$190.94M(m)$302.41M$70.94M$54.00K
2019-12-31Reported-$174.69M(m)(m)(m)-2159.00%$8.94M-$129.63M(m)$148.47M$37.60M$154.00K
2018-12-31Reported-$117.07M(m)(m)(m)-1097.43%$8.19M-$94.10M(m)$100.23M(m)-$480.00K
2017-12-31Reported-$81.24M(m)(m)(m)-3000.07%$2.74M-$66.38M(m)$62.51M(m)-$10.92M

Similar stocks

Stock NameCountryMarket CapPE Ratio
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Vericel Corp (VCEL)United States$2.011B93.97
Immunocore Holdings plc (IMCR)$1.613B-90.43
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40